Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Santa Monica, California and other locations
Dates
study started
completion around
Principal Investigator
by Zev Wainberg

Description

Summary

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

Official Title

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer

Details

Keywords

Metastatic Colorectal Cancer, mCRC, Colorectal Neoplasms, Bevacizumab, Etrumadenant, Zimberelimab, m-FOLFOX-6 regimen, Regorafenib, AB680 + Etrumadent+ Zimberelimab

Eligibility

Locations

  • UCLA Hematology Oncology
    Santa Monica California 90404 United States
  • City of Hope Comprehensive Cancer Center
    Duarte California 91010 United States

Lead Scientist at UCLA

  • Zev Wainberg
    Zev Wainberg, M.D., holds the Estelle, Abe, and Marjorie Sanders Chair in Cancer Research.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Arcus Biosciences, Inc.
Links
ARC-9 - Public website
ID
NCT04660812
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
About 227 people participating
Last Updated